MindRank AI
Latest round
- Series B
Last raised
- Jul 2026
Total raised
- $79M
Investors
- 8
About MindRank AI
, trading under the name MindRank AI, provides artificial intelligence-driven drug discovery platforms for the biotechnology sector. In March 2021, the company's AI Pharma Solution was recognized by Deep Pharma Intelligence as one of the 11 Most Important AI Drug Development Breakthrough Achievements in the World 2018-2020.S. FDA and China. Meanwhile, the company's partners include Medicilon, Antengene and other pharmaceutical companies. The CEO is Zhangming Niu. The company works with pharmaceutical enterprises to provide artificial intelligence-assisted drug design platforms, including the Molecule Arts Platform (MAP). This platform integrates biological, chemical, computational, and clinical data to support target research, molecular design, and multi-parameter optimization. The company also develops proprietary drug pipelines, such as the MDR-001 oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the MRANK-106 dual WEE1/YES1 kinase inhibitor for oncology.
Who invested in MindRank AI
8 investors across 4 rounds
See all investors in MindRank AI
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MindRank AI
Who invested in MindRank AI?
MindRank AI has 8 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MindRank AI raised?
MindRank AI has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did MindRank AI last raise money?
MindRank AI's most recent round on record is a Series B, in Jul 2026.
What does MindRank AI do?
, trading under the name MindRank AI, provides artificial intelligence-driven drug discovery platforms for the biotechnology sector.
Where is MindRank AI headquartered?
MindRank AI is headquartered in Hangzhou, China.
Which VCs invest in companies like MindRank AI?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at MindRank AI's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MindRank AI? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.